Other analysts have also recently issued reports about the company. Deutsche Bank raised their target price on Shire from GBX 4,500 ($58.62) to GBX 4,900 ($63.83) and gave the stock a buy rating in a research note on Wednesday, August 1st. Liberum Capital reissued a hold rating on shares of Shire in a research note on Tuesday, July 10th. Shore Capital restated a hold rating on shares of Shire in a report on Monday, July 2nd. Berenberg Bank lowered shares of Shire to a hold rating and raised their price objective for the stock from GBX 4,500 ($58.62) to GBX 5,000 ($65.13) in a report on Thursday, September 6th. Finally, UBS Group restated a neutral rating and issued a GBX 4,500 ($58.62) price objective on shares of Shire in a report on Wednesday, August 1st. Eight investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of GBX 4,693.14 ($61.13).
LON SHP opened at GBX 4,624 ($60.23) on Monday. Shire has a 1 year low of GBX 2,940.50 ($38.30) and a 1 year high of GBX 5,021 ($65.40).
The business also recently disclosed a dividend, which will be paid on Friday, October 19th. Shareholders of record on Thursday, September 6th will be issued a GBX 4.26 ($0.06) dividend. The ex-dividend date is Thursday, September 6th. This represents a yield of 0.1%.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.